Synthetic Biologics, Inc. (NYSEAMERICAN:SYN – Get Free Report) shares shot up 1% during mid-day trading on Monday . The stock traded as high as $1.02 and last traded at $1.02. 57,700 shares changed hands during trading, a decline of 71% from the average session volume of 197,338 shares. The stock had previously closed at $1.01.
Synthetic Biologics Price Performance
The company has a market capitalization of $16.16 million, a PE ratio of -0.84 and a beta of 1.38.
About Synthetic Biologics
Synthetic Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
Featured Stories
- Five stocks we like better than Synthetic Biologics
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- What does consumer price index measure?
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Discover the 3 Best Performing Stocks That Went Public in 2024
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
